Use of Omega-3 poyunsaturated Fatty Acid Supplements to Maintain Sinus Rhythm in Persistent Atrial Fibrillation:a prospective and randomised study. - Omega-3 PUFAs,atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001354-25-GB

Enrollment

Unknown

Registered

2005-06-30

Start date

2005-07-26

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with persistent atrial fibrillation

Interventions

Trade Name: Omacor Product Name: Omega-3 Product Code: PL15905/0001 Pharmaceutical Form: Capsule* Pharmaceutical form of the placebo: Capsule* Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with persistent atrial fibrillation scheduled for elective cardioversion of 18 to 80 yrs of age Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients on anti-arrythmic drugs,left atrial size>6cm,significant mitral valve disease,M.I. in the last 3 months

Design outcomes

Primary

Measure	Time frame
Main Objective: To maintain sinus rhythm after cardioversion ;Secondary Objective: ;Primary end point(s): Time to first electrocardiographicaly confirmed recurrence of atrial fibrillation/flutter lasting more than 10 minutes	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026